Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/17473
Citations | ||
Scopus | Web of ScienceĀ® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Update on anti-emetics for chemotherapy-induced emesis |
Author: | Olver, I. |
Citation: | Internal Medicine Journal, 2005; 35(8):478-481 |
Publisher: | Blackwell Publishing Asia |
Issue Date: | 2005 |
ISSN: | 1444-0903 1445-5994 |
Abstract: | The need to control chemotherapy-induced emesis has stimulated research into anti-emetics. Emesis is not only unpleasant, but negatively impacts on global quality of life. The development of two new classes of drugs has been responsible for the major advances in anti-emesis. The 5 hydroxytryptamine3 (5HT3) antagonists in combination with dexamethasone significantly improved the control of acute post chemotherapy emesis, but delayed emesis which can last for several days was still problematic, yet its incidence was underestimated by clinicians. Both the control of acute and delayed emesis was improved when the neurokinin1 (NK1) receptor antagonists were added to 5HT3 antagonists and steroids. The complete control of delayed emesis was improved by 21% with little toxicity. The triple drug combination has become the standard of care for preventing the emesis associated with cytotoxic drugs of high emetic potential. |
Keywords: | Humans Neoplasms Vomiting Ondansetron Granisetron Indoles Isoquinolines Quinolizines Quinuclidines Antiemetics Antineoplastic Combined Chemotherapy Protocols Prognosis Treatment Outcome Administration, Oral Drug Administration Schedule Dose-Response Relationship, Drug Quality of Life Patient Satisfaction Australia Female Male Tropisetron Palonosetron |
DOI: | 10.1111/j.1445-5004.2005.00879.x |
Published version: | http://dx.doi.org/10.1111/j.1445-5004.2005.00879.x |
Appears in Collections: | Aurora harvest 6 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.